Navigation Links
SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
Date:12/8/2008

DUBLIN, Calif., Dec. 8/PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its oral PIM kinase inhibitor, SGI-1776, is effective both in vitro and in vivo in preclinical models of acute lymphoblastic leukemia (ALL) (Abstract #1922). This research was presented at the 50th Annual Meeting of the American Society of Hematology.

In a poster presentation entitled "Inhibiting PIM-1 is effective in vitro and in vivo against ALL: A novel mechanistic and potentially clinically relevant druggable target," Dr. Valerie Brown and colleagues from Children's Hospital of Philadelphia and University of Pennsylvania demonstrated that SGI-1776 inhibited human ALL cell lines in a dose-dependent manner. Furthermore, SGI-1776 and the m-tor inhibitor rapamycin acted synergistically to inhibit ALL cell proliferation. In a clinically relevant in vivo model, NOD/SCID mice xenografted with human primary ALL cells, SGI-1776 also reduced tumor burden.

"Our PIM kinase inhibitor, SGI-1776, has significant potential in hematologic malignancies," commented Dr. Gregory Berk, Chief Medical Officer of SuperGen. "PIM-1 is known to be overexpressed in ALL, AML, CML, as well as non-Hodgkin's lymphoma. In many of these conditions PIM-1 overexpression is a poor prognostic factor. It has been postulated that inhibition of PIM kinase may potentiate the activity of m-tor inhibitors by modulation of m-tor inhibitor resistance pathways. These elegant preclinical experiments by Dr. Brown and her colleagues at the University of Pennsylvania support this hypothesis."

SuperGen recently received clearance for a phase I trial with SGI-1776 in patients with non-Hodgkin's lymphoma and prostate cancer, and plans to initiate a second phase I trial of SGI-1776 in patients with relapsed/refractory leukemias in 2009.

Copies of the poster presentations at the ASH Annual Meeting are available in the pipeline section of SuperGen's Web site www.supergen.com.

About SGI-1776

SGI-1776 inhibits the three human PIM kinases (PIM-1, PIM-2 and PIM-3). PIM kinases are highly conserved serine-threonine kinases that are key regulators in many signaling pathways implicated in cancer. When expressed, PIM kinases are strong survival factors and can induce progression of the cell cycle, inhibition of apoptosis, and modulation of other signal transduction pathways. Therefore, SGI-1776 can induce cell death in cancer cells expressing PIM kinases and promote sensitivity of cancer cells to treatment with other targeted and chemotherapy drugs. SGI-1776 has broad potential as a single agent as well as in combination with other agents, as PIM kinases contribute to many malignancies including prostate adenocarcinomas, diffuse large cell lymphomas, as well as several types of leukemias.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

    Contacts
    Timothy L. Enns
    SuperGen, Inc.
    SVP, Corporate Communications & Business Development
    Tel: (925) 560-2810
    E-mail: tenns@supergen.com

    Michael Beckerich
    Dorland Global Public Relations
    Media
    Tel:  (212) 677-7632
    mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
2. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
3. SuperGens PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
4. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
5. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
6. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
9. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
10. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
11. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):